Article · 26 Jun 2026
Conference abstractPublished 23 Jun 2025
Atypical Mycobacterium: A Challenge in the Treatment of Pemphigus Vulgaris
Ashford and St Peter's Hospitals NHS Foundation Trust,United Kingdom
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Pemphigus Vulgaris (PV) is an autoimmune acantholytic blistering disease that affects the skin and mucous membranes. It is due to autoantibodies targeted against adhesion molecules desmoglein 1 and 3 in the epidermis. Rituximab is now recommended as a first-line treatment for moderate to severe PV. Here in this case report we present a case of refractory PV complicated by atypical mycobacterium infection with a patient who has developed side effects of long-term high-dose steroid use. Observation: In March 2022 a fifty-eight-year-old male presented to his general practitioner with painful blisters in his mouth and on his scalp and body. He had no past medical history of note. He was referred to dermatology with a preliminary diagnosis of PV and was initiated on 1g mycophenolate mofetil BD, prednisolone 60mg and received monthly intravenous immunoglobulins. Unfortunately, after repeated rounds of treatment, the PV was not well controlled and he was later referred to a tertiary centre for Rituximab treatment in 2023. The PV had stabilised on the Rituximab but he had been getting recurrent painful and purulent abscesses on his chest and back. His initial skin swabs grew normal skin flora and moderate pseudomonas and as per microbiology recommendation was treated with repeated courses of Ciprofloxacin. This helped in the initial phase but the abscesses would shortly return after the course had been completed. Further to this, an excision biopsy from an abscess on his back was sent to histology for analysis including mycobacterium culture. The preliminary results from the skin biopsy showed that he had been positive for acid alcohol fast bacteria (AAFB). During this patient's 2 years of treatment, he developed; steroid-induced diabetes, steroid-induced myopathy and osteoporosis. Discussion: Every patient with PV poses a unique challenge in terms of disease control and adverse events. Corticosteroids have been the mainstay of treatment of PV since the time of their approval in the 1950s. Prolonged and high-dose administration of steroids is often needed to control certain autoimmune diseases such as PV. Corticosteroids long-term have severe adverse effects, including hypertension, osteoporosis, atherosclerosis, peptic ulcer disease, aseptic necrosis, diabetes mellitus and increased susceptibility to infections. Recently, rituximab, a chimeric anti-CD20 monoclonal antibody, which causes B-cell depletion, has been shown to improve disease remission rates with faster tapering of steroids compared to the conventional treatment. Rituximab is now recommended as a first-line treatment for moderate to severe PV. From this case, we have shown that the treatment of PV can be a challenging and complicated journey. Steroids are the first-line therapy for PV, but long-term administration may lead to serious adverse effects and this needs to be addressed when counselling a patient on long-term treatment.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cosmetology & Trichology.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cosmetology & Trichology
- SubjectDermatology
- BylineArticles whose byline prints “E. Wales”
